Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 7141-7150 Newer>

The Motley Fool February 3, 2011 Brian Orelli	Get Ready for Merck's Bumpy Ride Long-term earnings guidance gets thrown out the window.
Chemistry World February 3, 2011 Ben Merison	The mystery of the disappearing crystals UK chemists have analysed a fifty year old sample to find out why and say that it's down to impurities. This takes researchers a step closer to understanding why certain pharmaceutical drugs lose their therapeutic effect.
The Motley Fool February 3, 2011 Owain Bennallack	Glaxo Sweetens a Bitter Pill The drugmaker reports a loss, but resumes share buybacks.
The Motley Fool February 3, 2011 Brian Orelli	Add This Stock to Your Show-Me List Wait for the turnaround before investing in Boston Scientific; if it ever comes.
The Motley Fool February 3, 2011 Thomas Lee	Boston Scientific Wants to Be a Rock Star. But First, It Needs Some Stars Boston Scientific has been talking the talk of late. But its walk the past few years can be best described as a limp.
Chemistry World February 2, 2011 Andy Extance	Pfizer to close historic UK site Most of the 2400 people employed at the Pfizer site in Sandwich, UK, will be made redundant over the next 18-24 months as the US pharma giant restructures its research operations.
The Motley Fool February 2, 2011 Bryan Hinmon	Are Home Health Stocks Too Cheap? Home health agency stocks are cheap -- is now a time to buy?
The Motley Fool February 2, 2011 Brian Orelli	Pfizer's Newest Acquisition Target The pharma giant decided to cut potential acquisitions from its revenue guidance and instead spend the money on share buybacks.
The Motley Fool February 2, 2011 Brian Orelli	A Deeper Dive Into Biogen's Revenue Growth On the surface, it looks like Biogen Idec is handling the entrance of Novartis' new oral multiple sclerosis drug, Gilenya, quite well. The real picture is a little bleaker.
The Motley Fool February 1, 2011 Brian Orelli	Orexigen Falls Short Its obesity drug fails in the final mile of the drug-development marathon.
<Older 7141-7150 Newer> Return to current articles.